Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2026)
Vir Biotechnology (VIR) posted Accumulated Expenses of $68.1 million for Q1 2026, down 17.95% sequentially from $83.0 million in Q4 2025, and down 34.59% YoY from $104.1 million in Q1 2025.
Vir Biotechnology (VIR) Accumulated Expenses (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Accumulated Expenses for 9 years, with the latest figure at $68.1 million in Q1 2026.
- Quarterly Accumulated Expenses fell 34.59% year-over-year to $68.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.1 million (down 34.59% YoY) and the FY2025 annual result came in at $83.0 million, down 15.74% from the prior year.
- Accumulated Expenses slipped to $68.1 million in Q1 2026 per VIR's latest filing, from $83.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $489.1 million in Q4 2022 and troughed at $7.7 million in Q1 2022.
- A 5-year average of $163.8 million and a median of $98.5 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 89.01% in 2022, then soared 5821.06% in 2023.
- Over 5 years, Accumulated Expenses stood at $489.1 million in 2022, then tumbled by 78.69% to $104.2 million in 2023, then decreased by 5.47% to $98.5 million in 2024, then decreased by 15.74% to $83.0 million in 2025, then decreased by 17.95% to $68.1 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $68.1 million, $83.0 million, and $68.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.21 Mn |
| Mar 31, 2026 | 68.11 Mn |
| Dec 31, 2025 | 83.01 Mn |
| Sep 30, 2025 | 68.38 Mn |
| Jun 30, 2025 | 82.66 Mn |
| Mar 31, 2025 | 104.13 Mn |
| Dec 31, 2024 | 98.52 Mn |
| Sep 30, 2024 | 94.66 Mn |
| Jun 30, 2024 | 75.32 Mn |
| Mar 31, 2024 | 72.26 Mn |
| Dec 31, 2023 | 104.22 Mn |
| Sep 30, 2023 | 146.11 Mn |
| Jun 30, 2023 | 197.58 Mn |
| Mar 31, 2023 | 455.92 Mn |
| Dec 31, 2022 | 489.09 Mn |
| Sep 30, 2022 | 282.62 Mn |
| Jun 30, 2022 | 354.09 Mn |
| Mar 31, 2022 | 7.70 Mn |
| Dec 31, 2021 | 236.51 Mn |
| Sep 30, 2021 | 64.85 Mn |